TELA Bio, Inc. (TELA) |
| 0.5603 -0.007 (-1.25%) 04-13 16:00 |
| Open: | 0.59 |
| High: | 0.59 |
| Low: | 0.55 |
| Volume: | 200,618 |
| Market Cap: | 25(M) |
| PE Ratio: | -0.68 |
| Exchange: | NASDAQ Global Market |
| Industry: | Medical - Devices |
| Sector: | Healthcare |
| Technical analysis | ||||
![]() |
||||
| sell | buy | |||
| Resistance 2: | 0.92 |
| Resistance 1: | 0.76 |
| Pivot price: | 0.65 |
| Support 1: | 0.50 |
| Support 2: | 0.42 |
| 52w High: | 2.2 |
| 52w Low: | 0.501 |
TELA Bio, Inc., a commercial-stage medical technology company, focuses on providing soft-tissue reconstruction solutions that optimize clinical outcomes by prioritizing the preservation and restoration of the patient's anatomy. It provides a portfolio of OviTex Reinforced Tissue Matrix (OviTex) products for hernia repair and abdominal wall reconstruction; and OviTex PRS Reinforced Tissue Matrix products to address the unmet needs in plastic and reconstructive surgery, as well as OviTex for Laparoscopic and Robotic Procedures, a sterile reinforced tissue matrix derived from ovine rumen with polypropylene fiber intended to be used in laparoscopic and robotic-assisted hernia surgical repairs. The company markets its products through a single direct sales force, principally in the United States. TELA Bio, Inc. was incorporated in 2012 and is headquartered in Malvern, Pennsylvania.
| EPS | -0.830 |
| Book Value | 0.140 |
| PEG Ratio | 0.00 |
| Gross Profit | 1.223 |
| Profit Margin (%) | -48.37 |
| Operating Margin (%) | -31.86 |
| Return on Assets (ttm) | -25.1 |
| Return on Equity (ttm) | -223.4 |
Sat, 11 Apr 2026
TELA Bio (TELA) price target decreased by 34.78% to 2.30 - MSN
Fri, 27 Mar 2026
Citizens cuts Tela Bio stock price target on commercial transition - Investing.com
Wed, 25 Mar 2026
Jefferies cuts TELA Bio stock price target on slower growth outlook - Investing.com
Tue, 24 Mar 2026
TELA Bio (NASDAQ: TELA) lifts 2025 sales 16% but posts $38.8M loss - Stock Titan
Tue, 24 Mar 2026
TELA Bio Reports Fourth Quarter and Full Year 2025 Financial Results - GlobeNewswire
Tue, 24 Mar 2026
TELA Bio, Inc. (TELA) Reports Q4 Loss, Lags Revenue Estimates - Yahoo Finance
|
StockChart iOS |
StoxlineLite iOS |
StoxlineLite iOS |
OptionCalc iOS |
|
StockChart Android |
StoxlineLite Android |
StoxlinePro Android |
OptionCalc Android |